Literature DB >> 14695047

Cognitive impairment associated with atorvastatin and simvastatin.

Deborah S King1, Amanda J Wilburn, Marion R Wofford, T Kristopher Harrell, Brent J Lindley, Daniel W Jones.   

Abstract

Clinical guidelines for cholesterol testing and management have been updated recently. With the evolving recognition of benefits and intensified recommendations for cholesterol management, many more patients will require cholesterol-lowering drugs. All the statins share similar adverse-effect profiles, with a low overall frequency of undesirable effects. Emerging data associate statins with a decreased risk of Alzheimer's disease; however, we report two women who experienced significant cognitive impairment temporally related to statin therapy. One woman took atorvastatin, and the other first took atorvastatin, then was rechallenged with simvastatin. Clinicians should be aware of cognitive impairment and dementia as potential adverse effects associated with statin therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14695047     DOI: 10.1592/phco.23.15.1663.31953

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  36 in total

1.  Long-term atorvastatin treatment leads to alterations in behavior, cognition, and hippocampal biochemistry.

Authors:  Jan M Schilling; Weihua Cui; Joseph C Godoy; Victoria B Risbrough; Ingrid R Niesman; David M Roth; Piyush M Patel; John C Drummond; Hemal H Patel; Alice E Zemljic-Harpf; Brian P Head
Journal:  Behav Brain Res       Date:  2014-03-19       Impact factor: 3.332

Review 2.  Should we lower cholesterol as much as possible?

Authors:  Uffe Ravnskov; Paul J Rosch; Morley C Sutter; Mark C Houston
Journal:  BMJ       Date:  2006-06-03

Review 3.  Non-traditional dosing of statins in statin-intolerant patients-is it worth a try?

Authors:  Marc-Andre Cornier; Robert H Eckel
Journal:  Curr Atheroscler Rep       Date:  2015       Impact factor: 5.113

Review 4.  Coronary heart disease risk factors and outcomes in the twenty-first century: findings from the REasons for Geographic and Racial Differences in Stroke (REGARDS) Study.

Authors:  Hemal Bhatt; Monika Safford; Stephen Glasser
Journal:  Curr Hypertens Rep       Date:  2015-04       Impact factor: 5.369

Review 5.  Cognitive effects of statin medications.

Authors:  Brendan J Kelley; Stephen Glasser
Journal:  CNS Drugs       Date:  2014-05       Impact factor: 5.749

6.  Effect of atorvastatin on memory in albino mice.

Authors:  Rinku Rani Biswas; Das M C; Srinivasa Rao A S R; Sldv Ramana Murty Kadali
Journal:  J Clin Diagn Res       Date:  2014-11-20

7.  PCSK9 Variants, Low-Density Lipoprotein Cholesterol, and Neurocognitive Impairment: Reasons for Geographic and Racial Differences in Stroke Study (REGARDS).

Authors:  Matthew T Mefford; Robert S Rosenson; Mary Cushman; Michael E Farkouh; Leslie A McClure; Virginia G Wadley; Marguerite R Irvin; Vera Bittner; Monika M Safford; Ransi Somaratne; Keri L Monda; Paul Muntner; Emily B Levitan
Journal:  Circulation       Date:  2017-11-16       Impact factor: 29.690

Review 8.  Neuropsychiatric adverse events associated with statins: epidemiology, pathophysiology, prevention and management.

Authors:  Marco Tuccori; Sabrina Montagnani; Stefania Mantarro; Alice Capogrosso-Sansone; Elisa Ruggiero; Alessandra Saporiti; Luca Antonioli; Matteo Fornai; Corrado Blandizzi
Journal:  CNS Drugs       Date:  2014-03       Impact factor: 5.749

9.  Association of statin use with sleep disturbances: data mining of a spontaneous reporting database and a prescription database.

Authors:  Mitsutaka Takada; Mai Fujimoto; Kohei Yamazaki; Masashi Takamoto; Kouichi Hosomi
Journal:  Drug Saf       Date:  2014-06       Impact factor: 5.606

10.  Effects of atorvastatin on higher functions.

Authors:  G P Parale; N N Baheti; P M Kulkarni; N V Panchal
Journal:  Eur J Clin Pharmacol       Date:  2006-02-18       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.